This approach serves two purposes: it allows your body to adapt to the medication's effects (particularly gastrointestinal side effects such as nausea) and ensures that dose increases occur as you approach or reach steady state, optimising therapeutic response
How IGF-1 LR3 Supports Cell Growth and Repair Now that we have covered the definition, lets look at the practical application
IGF-1 is produced in response to physiological or pharmaceutical growth hormone (GH), and is responsible for many of the anabolic effects of GH
Dosing Comparison# Survodutide Dosing# Based on Phase 2 trial data and ongoing Phase 3 protocols: Route : Once-weekly subcutaneous injection Dose escalation : Starting dose of 0.25 mg with gradual titration Maintenance doses studied : 2.4 mg, 4.8 mg, and 6.0 mg weekly in Phase 2 Optimal dose : 4.8 mg and 6.0 mg showed greatest efficacy in Phase 2 weight loss trials MASH dosing : Similar dose range evaluated in hepatic endpoints trials Titration rationale : Gradual escalation minimizes GI side effects and allows metabolic adaptation to glucagon receptor activation Tirzepatide Dosing# FDA-approved dosing protocols: Route : Once-weekly subcutaneous injection Starting dose : 2.5 mg weekly for 4 weeks Dose escalation : Increase by 2.5 mg every 4 weeks as tolerated Maintenance doses : 5 mg, 10 mg, or 15 mg weekly Maximum dose : 15 mg weekly Formulation : Prefilled single-dose pens (Mounjaro/Zepbound) and prefilled syringes Storage : Refrigerated
M2 macrophages, as infiltration-rich immunosuppressive cells, are able to activate the PI3K/AKT/mTOR signaling axis by secreting IGF-1 and IGF-2, which promotes thyroid cancer cell invasion and the expression of stemness markers (Oct4, SOX2 and CD133), exacerbating the immunosuppressive effects of cancer (74)
